Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine and Oxaliplatin (CAPOX) in Advanced Pancreatic Cancer
NCT00585078Phase 2Completed
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- May 2004
- Primary completion
- Dec 2011
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and oxaliplatin in pancreatic ductal adenocarcinoma (PDAC), sponsored by Beth Israel Deaconess Medical Center. Primary endpoint: Response Rate. Started May 2004; status: completed.
02
Drugs
capecitabineoxaliplatin
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00585078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00585078.